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Background: Systemic inflammation may contribute to cachexia in patients with chronic obstructive pulmonary
disease (COPD). In this longitudinal study we assessed the association between circulating C-reactive protein (CRP),
tumor necrosis factor (TNF)-α, interleukin (IL)-1ß, and IL-6 levels and subsequent loss of fat free mass and fat mass in
more than 400 COPD patients over three years.
Methods: The patients, aged 40–76, GOLD stage II-IV, were enrolled in 2006/07, and followed annually. Fat free
mass and fat mass indexes (FFMI & FMI) were calculated using bioelectrical impedance, and CRP, TNF-α, IL-1ß, and
IL-6 were measured using enzyme immunoassays. Associations with mean change in FFMI and FMI of the four
inflammatory plasma markers, sex, age, smoking, FEV1, inhaled steroids, arterial hypoxemia, and Charlson
comorbidity score were analyzed with linear mixed models.
Results: At baseline, only CRP was significantly (but weakly) associated with FFMI (r = 0.18, p< 0.01) and FMI
(r = 0.27, p< 0.01). Univariately, higher age, lower FEV1, and use of beta2-agonists were the only significant
predictors of decline in FFMI, whereas smoking, hypoxemia, Charlson score, and use of inhaled steroids predicted
increased loss in FMI. Multivariately, high levels of TNF-α (but not CRP, IL-1ß or IL-6) significantly predicted loss of
FFMI, however only in patients with established cachexia at entry.
Conclusion: This study does not support the hypothesis that systemic inflammation is the cause of accelerated loss
of fat free mass in COPD patients, but suggests a role for TNF-α in already cachectic COPD patients.
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Chronic obstructive pulmonary disease (COPD) afflicts
approximately 9-10% of adults over 40 years of age [1],
and is a source of considerable comorbidity and mortal-
ity to those afflicted [2,3]. A common complication in
COPD is loss of skeletal muscle mass. Roughly 25% of
COPD patients will develop cachexia [4], which by itself
is associated with increased mortality [5].
Patients with COPD exhibit chronic inflammation in
the airways, and several studies have shown higher sys-
temic levels of inflammatory markers in patients with* Correspondence: tomas.eagan@med.uib.no
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reproduction in any medium, provided the orCOPD compared with subjects without COPD [6-9].
Several authors have suggested that this systemic inflam-
mation is a causal factor in the development of compli-
cations and comorbidities in patients with COPD,
including the development of cachexia [10-12].
It is still controversial whether the increased systemic
levels of inflammation represent a chronic, systemic in-
flammatory process or reflect spillover into the systemic
bloodstream of inflammatory byproducts from the lungs
without consequences [13]. Regardless of the source of
the systemic inflammatory markers, increased levels
could be a factor in the development of extra-pulmonary
manifestations in COPD. This is a particularly attractive
theory regarding Tumor Necrosis Factor alpha (TNF-α)
and the development of cachexia in COPD. TNF-α, ori-
ginally termed cachexin, is produced by a variety of im-
mune cells, and is together with Interleukin-1ß and −6td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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acute-phase response, including production of C-
Reactive Protein (CRP). It has long been thought that
prolonged exposure to TNF-α contributes to cachexia in
cancer patients [14]. Thus, it would seem reasonable
that higher systemic levels of CRP, TNF-α, IL-1ß, and
IL-6 could be contributing factors to cachexia also in
COPD patients.
So far, only cross-sectional studies have been published
on levels of these inflammatory markers and body com-
position in patients with COPD, with some studies find-
ing higher TNF-α in underweight COPD patients [15-18],
whereas other studies have not [19-22].
The aim of the current study was to examine pro-
spectively the relationship between the systemic inflam-
matory markers CRP, TNF-α, IL-1ß and IL-6 and loss of
fat free mass over a 3-year time period, using data from
the Bergen COPD Cohort Study in Western Norway.
We hypothesized that patients with high levels of these
molecules on entry would have a higher rate of decline
in free fat mass over the next three years.
Methods
Study population
The study sampling and data collection in the baseline
phase of the Bergen COPD Cohort Study have been
published previously [7]. Briefly, in 2006/07, 426 COPD
patients were enrolled, aged 40–76 years, with a clinical
diagnosis of COPD, GOLD stage II or worse, and a
smoking history of more than 10 pack-years. All patients
received written and oral information prior to participa-
tion, and signed informed consent. The regional ethical
committee (REK-Vest) approved the study.
All patients were examined at baseline, and attempted
followed-up yearly. 388 patients (91%) participated at
the one-year visit, 374 (88%) at the two-year visit, and
360 (85%) at the three-year visit. Eleven patients who
used oral steroids were excluded from the study sample
for the current study. For seven patients we lacked valid
plasma samples, thus the initial study sample consisted
of 408 patients.
Data collection
A physician performed a structured interview, measured
arterial blood gases, and provided health care as needed.
Bioelectrical impedance was measured with a Bodystat
1500 (Bodystat Ltd, Douglas, Isle of Man, UK), and all
patients were fasting prior to the visits. The reliability of
bioelectrical impedance measurements has been previ-
ously described [23]. The fat free mass index (FFMI) and
fat mass index (FMI) was calculated as the fat free mass
(kg) or fat mass (kg) respectively, divided by the square
of height (m2). A reliability study was performed for
quality control of the impedance measurements. TenCOPD patients and 10 healthy volunteers were mea-
sured 10 times each within one hour. The coefficient of
variance for FFMI was 0.47 for the patients and 0.54 for
the healthy controls, and for FMI 1.14 for the patients
and 2.09 for the controls. Cachexia was defined as hav-
ing a FFMI less than 14 kg/m2 for women and less than
17 kg/m2 for men [4], which corresponds to the lower
95% confidence limit in a normal population [24].
For the current study, available plasma samples from
baseline (n = 408) and the one-year (n = 382) visits were
analyzed. The outcomes were change in FFMI and FMI,
measured at baseline (n = 405) and the one- (n = 369),
two- (n = 336), and three- (n = 339) year visits.
Laboratory measurements
Plasma samples were drawn into pyrogen-free blood col-
lection tubes with EDTA and centrifuged within 30 min-
utes at 2150 X g for 15 minutes at 4°C. All samples were
stored at −80°C.
TNF-α, IL-1ß and IL-6 were measured using enzyme
immunoassays (EIA) kits from BD Biosciences Pharmin-
gen (San Diego, CA) and CRP using a high-sensitivity
EIA kit from R&D Systems (Minneapolis, MN). All sam-
ples from one patient were analyzed on the same ELISA
plate for each marker to reduce intra-subject inter-assay
variations. All measurements were performed in dupli-
cates and the averaged values were used.The detection
limit for IL-1ß, IL-6 and TNF-α was 0.5 pg/mL, whereas
for CRP it was 0.010 ng/ml and values below were
defined as 0. The intra-assay and inter-assay coefficient
of variations were <10% for all parameters.
Statistical analyses
For the four markers the distribution was left-skewed.
For the correlation analyses between all markers and the
body composition indices FFMI and FMI, Spearman’s
rank correlation tests were used. The levels of the cyto-
kines were generally low, with many patients having
levels below the detection limit for each of the visits.
Therefore, in addition to looking at the baseline levels of
each inflammatory marker we examined patients who
had a measured plasma level above the 75 percentile of
each marker both at entry and year 1 (“sustained high”),
compared with patients who did not.
To properly adjust for the correlation between the
repeated measurements of the outcome variables FFMI and
FMI, advanced longitudinal analyses are necessary. Cur-
rently, the two most used methods are linear mixed models
and generalized estimating equations (GEE) [25]. We ap-
plied linear mixed models using the xtmixed comand in
Stata, with an unstructured variance-covariance structure.
However, all analyses were also performed with generalized
estimating equations (GEE), with an exchangeable correla-
tions structure, for comparison.
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For the univariate analyses, for both the outcomes FFMI
and FMI we calculated one linear mixed model for each
predictor variable, which included the variable in ques-
tion, the effect of time (in years, coded as 0,1,2 or 3),
and the interaction term of variable * time. To obtain in-
terpretable intercepts, continuous predictor variables
were centered; the inflammatory markers around their
mean value, age around 60 years, and FEV1 around 50%
of predicted.
For each model the coefficient of the variable in ques-
tion thus represents the intercept, i.e. the effect of that
variable at baseline, and the coefficient of time repre-
sents the effect of time. The real interest lies in the coef-
ficients of the interaction term, as this specifies the
effect of change in the outcome over time. With our
coding of time as 0,1,2 and 3, the coefficients thus repre-
sents yearly change in mean FFMI or FMI.Multivariable analyses
The main outcome of interest in this study was whether
the plasma levels of the inflammatory markers predicted
change in FFMI or FMI. Thus, the most important con-
sideration with regards to the other variables like sex,
age, smoking and FEV1 was to ensure adequate adjust-
ment for possible confounding variables. For the multi-
variable analyses, we chose the following modeling
strategy: We fitted one model for each inflammatory
marker for each outcome, in which each model included
the effect of sex, age, cachexia, smoking, FEV1 in percent
predicted, hypoxemia, Charlson Index, exacerbations the
last year prior to inclusion, use of inhaled steroids, use
of long-acting ß2agonists (LABA), and use of theophyl-
line. Since several previous cross-sectional studies have
shown an association between cachexia and the levels of
some of these inflammatory markers, we tested for the
interaction between cachexia and the marker in question
for each model, with a significance level set at 0.05. All
analyses were performed with Stata 12.1.Results
The baseline characteristics of the cohort are presented
in Table 1. About half were at GOLD stage II, average
age was a little more than 60 years, and more than two
thirds used inhaled steroids at entry. Twenty-nine per-
cent were cachectic at entry to the study by the criteria
we used [4]. Patients lost to follow-up were older, had
more advanced COPD with more frequent exacerba-
tions, and with more comorbidities (Table 1). Among
male patients, FFMI was lower among patients lost to
follow-up (p = 0.02, Table 1). The baseline levels of the
four markers were not different between patients with
complete follow-up and patients lost to follow-up.The distribution of change in FFMI and FMI over the
three years of the study is shown in Figure 1.
Univariate analyses between independent variables and
FFMI or FMI
A correlation matrix of the four inflammatory markers
measured on entry (year 0) and at second visit (year 1),
as well as FFMI and FMI measured at these two visits, is
presented in Table 2. There were significant correlations
between the levels of each marker between the first and
second visit, strongest for CRP (correlation coefficient
0.75). There were also significant correlations between
the different cytokines, but weaker than the inter-visit
correlation for each marker. The only inflammatory
marker that consistently correlated with FFMI and FMI
at the first and second visit was CRP.
The unadjusted estimated yearly change in FFMI and
FMI for each inflammatory marker is shown in Table 3.
For example, in a patient with a measured value of 2.4 ug
CRP, the yearly decline in FFMI would be 0.0732 kg/m2.
For a patient with a measured level of CRP equal to 3.4
ug, the yearly decline in FFMI would be (0.0732-0.0121)
0.0611 kg/m2, whereas in a patient with measured level of
CRP 1.4, the yearly decline in FFMI would be
(0.0732+ 0.0121) 0.0853 kg/m2.
For neither FFMI nor FMI were the entry inflamma-
tory marker levels statistically significant predictors of
increased decline. However, in patients with a sustained
high level of CRP, there was a significant increase in
FFMI and decrease in FMI over three years.
Higher age, lower FEV1, and use of long-acting beta2-
agonists were the only significant predictors of an
increased decline in FFMI in the univariate analyses. For
decline in FMI, significant predictors were smoking his-
tory, arterial oxygen tension (PaO2) less than 8 kPa, the
presence of comorbidities, use of inhaled steroids
(Table 4). Exacerbation history the last year before entry
to the study, did not predict change in either FFMI or
FMI (Table 4).
Estimation with GEE gave reasonable accordance with
the results found with the linear mixed models, where
all coefficients where almost similar, but the confidence
intervals sometimes narrower (data not shown).
Multivariable analyses
After adjustment for all covariables, lower CRP and
lower IL-6 at baseline was significantly associated with
an increased decline in FFMI (Table 5). For CRP this
also held up when comparing patients with sustained
high levels to patients without, where the fastest decline
in FFMI was seen among patients without sustained
high levels of CRP.
Patients with a sustained high level of TNF-α (TNF-
α> 2.2 pg/mL, n = 54) at both year 0 and year 1, had a
Table 1 Baseline characteristics of the study sample and comparison with patients lost to follow-up
Women (n= 159) Men (n = 249) Lost to follow-up (n = 69) p**
Age, mean years (SD) 62.3 (6.7) 64.2 (7.0) 66.8 (5.9) <0.01
FFMI, mean kg/m2 (SD) 14.8 (2.4) 18.4 (3.0) -
FMI, mean kg/m2 (SD) 10.1 (4.3) 7.3 (2.5) -
% cachectic* 31.0 27.5 37.3 0.10
Smoking habits, n(%) 0.32
ex 88 (55.3) 144 (57.8) 43 (62.3)
current 71 (44.7) 105 (42.2) 26 (37.7)
GOLD stage <0.01
II 82 (51.6) 111 (44.6) 22 (31.9)
III 66 (41.5) 105 (42.2) 31 (44.9)
IV 11 (6.9) 33 (13.2) 16 (23.2)
Hypoxemia, n(%) <0.01
PaO2> 9 kPa 84 (61.3) 150 (64.4) 26 (44.1)
PaO2 8–9 kPa 33 (24.1) 56 (24.0) 17 (28.8)
PaO2< 8 kPa 20 (14.6) 27 (11.6) 16 (27.1)
Exacerbations last year, n(%) 0.01
0-1 126 (79.3) 214 (85.9) 50 (72.5)
2+ 33 (20.7) 35 (14.1) 19 (27.5)
Charlson Comorbidity Index <0.01
1 101 (63.5) 130 (52.2) 30 (43.5)
2 40 (25.2) 59 (23.7) 15 (21.7)
3 13 (8.2) 36 (14.5) 12 (17.4)
4+ 5 (3.1) 24 (9.6) 12 (17.4)
Use of inhaled steroids 0.19
No 40 (25.2) 88 (35.3) 17 (24.6)
Yes 119 (74.8) 161 (64.7) 52 (75.4)
Use of long-acting beta2 agonists 0.07
No 33 (20.8) 80 (32.1) 13 (18.8)
Yes 126 (79.2) 169 (67.9) 56 (81.2)
Use of theophyllin 0.02
No 144 (90.6) 228 (91.6) 58 (84.1)
Yes 15 (9.4) 21 (8.4) 11 (15.9)
CRP, mean ug/mL (SD) 2.4 (3.1) 2.4 (2.7) 2.5 (2.5) 0.35
TNF-α mean pg/mL (SD) 1.8 (3.4) 1.8 (3.3) 1.2 (2.5) 0.12
IL-1ß, mean pg/mL (SD) 0.8 (2.0) 1.0 (2.2) 1.0 (2.1) 0.77
IL-6, mean pg/mL (SD) 2.2 (6.8) 2.2 (5.5) 1.4 (2.7) 0.32
*defined as FFMI< 14 kg/m2 for women and <17 kg/m2 for men.
**for difference between baseline and lost to follow up; chi square for categorical variables and Kruskal Wallis test for continuous variables.
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patients without sustained high TNF-α (Table 5).
The only significant relationship between levels of the
inflammatory markers and change in FMI over time was
in patients with sustained high levels of CRP who had a
smaller increase in FMI than patients without sustained
high levels of CRP. (Table 5).Cachexia at baseline was not associated with acceler-
ated decline in either FFMI or FMI, neither in the uni-
variate analyses (Table 4), nor when included in the
multivariable analyses (data not shown).
For TNF-α there was a significant interaction with cach-
exia at baseline in patients with sustained high TNF-α at
year 0 and year 1 (p= 0.001). This is demonstrated in
Figure 1 Distribution of change in fat free mass index (FFMI) and fat mass index (FFMI) (kg/m2) over the 3 years of the study.
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FFMI for patients with and without a sustained high level
of TNF-α and with and without cachexia at baseline, cal-
culated from the coefficients from the multivariable re-
gression analysis. Figure 2 shows that only for COPD
patients who were cachectic did the slopes differ signifi-
cantly between patients with different levels of TNF-α.
Specifically, in already cachectic patients, sustained high
TNF-α levels were associated with greater decline in FFMI
than for those without sustained high TNF-α. However, inTable 2 Correlation coefficients for univariate relationships b
and first follow-up visit (year 1), and FFMI and FMI at those t
CRP,
year 0
CRP,
year 1
TNF-α
year 0
TNFα
year 1
IL-1ß,
year 0
IL
ye
CRP, year 0 1
CRP, year 1 0.75** 1
TNF-α year 0 −0.05 −0.10 1
TNF-α year 1 −0.02 −0.02 0.49** 1
IL-1ß, year 0 0.10 0.06 0.30** 0.20** 1
IL-1ß, year 1 0.05 0.08 0.21** 0.17** 0.47** 1
IL-6, year 0 0.17** 0.19** 0.27** 0.22** 0.24** 0.2
IL-6, year 1 0.11* 0.15** 0.17** 0.36** 0.08 0.1
FFMI, year 0 0.18** 0.13* −0.05 0.06 0.03 −0
FFMI, year 1 0.19** 0.15** −0.05 −0.01 0.08 0.0
FMI, year 0 0.27** 0.16** −0.04 0.06 0.05 −0
FMI, year 1 0.27** 0.15** −0.01 0.01 0.06 −0
* p< 0.05, ** p< 0.01; Spearman rank correlation coefficients.non-cachectic patients, sustained high TNF-α was not
associated with greater decline in FFMI.
Discussion
This is to our knowledge the first longitudinal study of
the relationships between the systemic inflammatory
markers CRP, TNF-α, IL-1ß and IL-6 and the change in
body composition over time in patients with COPD. The
main finding from this study was that, over 3 years, sus-
tained high TNF-α levels were associated with anetween plasma inflammatory markers at baseline (year 0)
wo visits
-1ß,
ar 1
IL-6,
year 0
IL-6,
year 1
FFMI,
year 0
FFMI,
year 1
FMI,
year 0
FMI,
year 1
0** 1
5** 0.43** 1
.04 0.08 0.10 1
0 0.10 0.03 0.95** 1
.01 0.02 0.10* 0.25** 0.30** 1
.02 0.01 0.03 0.26** 0.26** 0.93** 1
Table 3 Unadjusted yearly change in fat free mass index (FFMI) and fat mass index (FMI) for the four infalammatory
markers, estimated by linear mixed models
Yearly change in FFMI p-value Yearly change in FMI p-value
CRP
at CRP= 2.4 −0.0732 −0.0195
per 1 ug/mL increase 0.0121 0.10 −0.0041 0.63
Sustained high CRP at year 0 and 1
No −0.0828 0.0037
Yes 0.0320 0.046 −0.1421 0.02
TNF-α
at TNF-α= 1.8 −0.0597 −0.0236
per 1 pg/mL increase −0.0107 0.09 0.0020 0.77
Sustained high TNF-α at year 0 and 1
No −0.0488 −0.0283
Yes −0.1621 0.07 0.0366 0.36
IL-1ß
at IL-1ß = 0.93 −0.0611 −0.0234
per 1 pg/mL increase 0.0144 0.16 −0.0026 0.82
Sustained high IL-1ß at year 0 and 1
No −0.0723 −0.0216
Yes −0.0167 0.36 −0.0083 0.85
IL-6
at IL-6 = 2.8 −0.0613 −0.0234
per 1 pg/mL increase 0.0023 0.10 −0.0003 0.87
Sustained high IL-6 at year 0 and 1
No −0.0700 −0.0150
Yes −0.0251 0.49 −0.0558 0.58
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action analysis suggested this may be only in COPD
patients who were already cachectic at entry into the
study.Inflammation and loss of FFMI
COPD is a chronic inflammatory disorder, and several
studies have found increased levels of TNF-α, as well as
CRP and IL-6 both in bronchoalveolar lavage (BAL) [26]
and in the systemic circulation [26,27]. More import-
antly, some studies have shown higher systemic levels of
TNF-α in COPD patients with cachexia compared with
patients without cachexia [15-17]. However, the mea-
sured levels of TNF-α in BAL and blood correlate poorly
[13], and some studies have not found higher levels of
TNF-α in COPD patients with cachexia compared with
patients without cachexia [19,20,22].
In the current study, we have not compared the levels of
the markers to non-COPD subjects. Compared with levels
of inflammatory markers measured in other normal popu-
lations [28-30], our levels were higher. However, we cautionagainst over-interpretation of this, since methodology and
populations differed.
The measured levels of cytokines in the peripheral cir-
culation are usually quite low, partly due to the typical
‘burst secretion’ of the cytokines, and partly due to the
fact that there are many available soluble proteins to
which the cytokines can bind. Thus, to observe the po-
tential effects of a sustained increase of the pro-
inflammatory cytokines in the systemic circulation, a
sufficient patient sample is necessary, which has not al-
ways been the case with studies published so far. We
studied over 400 patients, 29% of whom were cachectic.
Longitudinal versus cross-sectional studies
Arguably, the most important missing pieces in the litera-
ture to date are longitudinal studies on humans. Although
cross-sectional studies may indicate an association be-
tween levels of an inflammatory marker and body com-
position, the rate of change in FFMI and FMI can only be
assessed with longitudinal data. We have previously shown
from a cross-sectional study on this cohort that CRP was
markedly increased in COPD patients compared with
Table 4 Unadjusted yearly change in fat free mass index (FFMI) and fat mass index (FMI) for each baseline predictor
variable, estimated bylinear mixed models
Baseline variables Yearly change in FFMI p-value Yearly change in FMI p-value
Sex
Women −0.0613 0.01599
Men −0.0662 0.91 −0.04131 0.24
Age
at age 60 −0.0377 −0.0024
per 10 yrs increase −0.0867 0.01 −0.0584 0.10
Smoking
Ex −0.0772 −0.0762
Current −0.0477 0.49 0.0531 0.01
GOLD stage
II 0.0024 0.0032
III −0.1151 0.01 −0.0333 0.47
IV −0.1861 0.01 −0.0921 0.27
FEV1
at 50% of predicted −0.0624 −0.0197
per 10% decrease in predicted value −0.0477 0.00 −0.0227 0.18
Hypoxemia
PaO2> 9 kPa −0.0664 0.0006
PaO2 8–9 kPa −0.0506 0.77 0.0270 0.65
PaO2< 8 kPa −0.1052 0.61 −0.2695 0.00
Exacerbations last year
0-1 −0.0618 −0.0115
2+ −0.0764 0.81 −0.0638 0.43
Charlson Comorbidity Score
I −0.0768 0.0378
II −0.0652 0.82 −0.0737 0.05
III 0.0333 0.11 −0.1616 0.01
IV+ −0.1231 0.62 −0.0962 0.20
Cachexia
No −0.0495 −0.0255
Yes −0.0983 0.31 −0.0089 0.76
Using inhaled steroids
No −0.0243 0.0610
Yes −0.0828 0.20 −0.0574 0.02
Use of long-acting beta2 agonists
No −0.0101 0.0696
Yes −0.0862 0.01 −0.0557 0.02
Use of theophyllin
No −0.0605 −0.0086
Yes −0.1097 0.54 −0.1421 0.14
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that fat mass, more than fat free mass, was associated with
elevated levels of CRP in COPD patients [31].In the current 3-year longitudinal study, we expand on
prior knowledge by showing that it was COPD patients
without sustained high levels of CRP that had the largest
Table 5 Adjusted* yearly change in fat free mass index (FFMI) and fat mass index (FMI) for plasma CRP, TNF-α, IL-1ß
and IL-6, estimated by linear mixed models with random effects
Yearly change in FFMI p-value Yearly change in FMI p-value
CRP at baseline
at CRP= 2.4 −0.0622 0.1355
per 1 ug/mL increase 0.0221 0.01 −0.0066 0.48
Sustained high CRP at year 0 and 1
No −0.0874 0.1494
Yes 0.0656 0.01 0.0061 0.03
TNF-α at baseline
at TNF-α= 1.8 −0.0531 0.1303
per 1 pg/mL increase −0.0098 0.13 0.0004 0.96
Sustained high TNF-α at year 0 and 1
No −0.0643 0.1287
Yes −0.2098 0.03 0.1366 0.91
IL-1ß at baseline
at IL-1ß = 0.93 −0.0424 0.1300
per 1 pg/mL increase 0.0147 0.16 0.0009 0.93
Sustained high IL-1ß at year 0 and 1
No −0.0685 0.1257
Yes −0.0341 0.58 0.1548 0.67
IL-6 at baseline
at IL-6 = 2.8 −0.0414 0.1302
per 1 pg/mL increase 0.0034 0.02 0.0004 0.79
Sustained high IL-6 at year 0 and 1
No −0.0676 0.1291
Yes 0.0231 0.18 0.1184 0.88
* Adjusted for the effect of change by the interaction between yearly change and each of the baseline variables sex, age, cachexia, FEV1, smoking, hypoxemia,
Charlson Index, number of exacerbations the last year, use of inhaled steroids, long acting beta2agonists, and use of theophylline.
Figure 2 The estimated change in FFMI based on the
regression coefficients from the interaction (p = 0.013) between
the effects of plasma levels of TNF-α on change in fat free
mass in cachectic and non-cachectic COPD patients.
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showed that COPD patients with higher systemic levels
of IL-1ß and IL-6 in general did not have a subsequently
increased decline in fat free mass or increase in fat mass.
Only one marker, TNF- α, and only in patients with a
high level both at year 0 and year 1, predicted an
increased decline in FFMI. However, the interaction ana-
lyses suggested that COPD patients with the same high
TNF-α levels who were not cachectic on entry did not
lose FFMI faster than their non-cachectic counterparts
with lower TNF-α.
Interpretation of the findings
If we accept the current findings, the question remains,
what do they mean?
There are several possible interpretations: First, in-
flammation may be a consequence rather than a cause
of initial loss of fat free mass, but may contribute to fur-
ther loss of fat free mass once the cachectic process has
started. Second, only a subgroup of patients respond to
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genetic and/or environmental differences between sub-
groups. Third, the patients who were cachectic at entry
may have had a longer exposure to inflammation before
entering the study, implying that the non-cachectic
patients with high TNF-α levels will develop cachexia if
followed longer. It would take and even bigger and far
longer study to distinguish among these possibilities –
one in which prior to starting to smoke, a young cohort
was followed until age 60–70 with similar measure-
ments. In that way, pre-tobacco influences on cytokine
levels could be established, time to develop COPD
would be recorded, and temporal relationships between
body composition and cytokine profiles established.
These possibilities could have therapeutic consequences,
since a TNF-α blocking agent presumably would not have
an effect before cachexia was already developed if the first
explanation was correct. Very few studies to date have
assessed anti- TNF-α treatment on cachexia, and only in
patients with cancer [32] or arthritis [33]. In neither of the
studies to date have the results been convincingly in favor
of anti- TNF-α treatment. Although there are no specific
trials to date on anti- TNF-α treatment for cachexia in
COPD, interesting circumstantial evidence is available
from a multi-centre trial of 220 COPD patients in North-
America, in which infliximab was tested against placebo
[34]. In patients who were cachectic and received inflixi-
mab 6-minute walking distance improved significantly
after 24 weeks, whereas patients who were not cachectic
did not benefit from the drug, supporting our findings that
TNF-α may be of consequence only in already cachectic
COPD patients.
Regarding change in FMI, baseline variables daily
smoking, use of inhaled steroids, and being hypoxemic
were associated with a larger loss of FMI, even in the
multivariable model (data not shown). Current smoking
is associated with a suppression of appetite, whereas use
of inhaled steroids could be a marker for disease sever-
ity. Patients with respiratory failure may exert them-
selves more at rest, thus burning more fat. However, we
caution against over-interpretation, as the analyses did
not take into account change in smoking habits, PaO2 or
medication use throughout the study. The main research
interest was whether plasma levels of the inflammatory
markers were predictive of subsequent change in body
composition, including changes in fat mass, and the im-
portance of the co-variables was to make sure we had
adequately adjusted for confounders.
Measurement considerations
The results of the current study are unlikely to be due
only to the inherent methodological difficulties. First, the
levels of the cytokines measured in the COPD patients
were about the same as other authors have reported inrecent studies [19,35]. Standard high-sensitivity ELISA
kits were used, all samples were analyzed in duplicate,
and all samples from the same subject were analyzed on
the same plate. Second, there was a positive, albeit weak,
correlation between the three cytokines at each year, as
expected. Third, we separately analyzed the predictive
value of a) the level of each of the cytokines at entry, and
b) a sustained high level of the cytokine for the first year,
with the same conclusion. Finally, we also analyzed the
predictive value of the cytokines at entry as categorical
variables (low, medium, high), and this also produced the
same result (data not shown): TNF-α was the only cyto-
kine associated with change in FFMI, and in already
cachectic COPD patients only.
The other potentially important methodological issue
is the measurement of change in FFMI and FMI. Over
the three years of the study, the mean yearly change in
both FFMI and FMI was not very large. However, even
though overall mean change was small, the range of
change was quite significant (Figure 1). This range
enables analyses of whether change in one group is sig-
nificantly different from change in another group.
Finally, the analyses of the socio-demographic and
clinical variables demonstrated significant and reason-
able predictors of change in lean body mass. Higher age
and lower FEV1 were significantly related to faster de-
cline in fat free mass, as expected.
In conclusion, this study did not find firm support for
the systemic inflammation hypothesis in causing COPD
cachexia, but raises the possibility that TNF-α contri-
butes to further loss of FFMI in patients who are already
cachectic, creating a vicious circle of ever increasing in-
flammation and loss of fat free mass.
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